Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility Study of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children with Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia or Lymphoma

NCT06866873 is registered in ClinicalTrials.gov with Hong Kong Children's Hospital as lead sponsor.

NCT NCT06866873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility Study of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children with Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia or Lymphoma
Lead sponsor
Hong Kong Children's Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
May 1, 2024
Completion date
December 31, 2037
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, pediatric, lymphoma, b-cell